ReviewClinical Medicine Insights. Cardiology2025
Controversies in Antithrombotic Therapy for Patients With Coronary Artery Disease and Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Literature Review.
Review in Clinical Medicine Insights. Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Possible clinical drug interactions between ticagrelor and concomitant medications: for adverse drug event monitoring in real-world.Cardiovascular drugs and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CAD and AF are 2 of the major cardiovascular challenges worldwide, often coexisting and complicating management strategies. PCI has revolutionized the treatment of CAD, reducing mortality and improving recovery. At the same time, AF increases the risk of stroke, thus requiring anticoagulation. The combination of antiplatelet and anticoagulant therapies in patients undergoing PCI is challenging because of increased bleeding risks. This literature review explores the controversies surrounding dual antithrombotic therapy (DAT) and triple antithrombotic therapy (TAT), evaluating their efficacy and safety in mitigating thrombotic and hemorrhagic risks. Key clinical trials and guidelines advocate the use of DAT, especially in patients at high bleeding risk, underlining its role in reducing complications without compromising ischemic protection. Furthermore, advances in stent technologies, personalized medicine tools, and pharmacogenomics have further refined treatment strategies toward tailored approaches. Despite these developments, the optimal duration of therapy remains debated, as do patient selection and the need to balance ischemic and bleeding risks, particularly in complex patients.This review underscores the need for an individualized, evidence-based approach to optimize outcomes and inform future guidelines in managing this high-risk population. Emerging therapies and real-world evidence-such as trials investigating Factor XI inhibitors and bioresorbable scaffolds-are promising, aiming to reduce bleeding risk and improve long-term outcomes in patients with CAD and AF. Additionally, newer DOACs are being evaluated for improved efficacy and safety profiles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.